Leukemia Recurrence: What to Ask

Leukemia is four broad diseases, and relapse means something different in each. What follows draws on NCI's summary for acute myeloid leukemia, with a separate section for acute promyelocytic leukemia, a subtype of AML.

If your diagnosis is acute lymphoblastic leukemia, chronic lymphocytic leukemia or chronic myelogenous leukemia, the definitions and the salvage options on this page do not transfer. Relapsed CML, for instance, is defined by NCI as any evidence of progression from a stable remission, including BCR::ABL1 turning up again on molecular testing, and NCI names further tyrosine kinase inhibitors such as ponatinib and asciminib for it. That is not a salvage chemotherapy conversation at all. Ask your team for the summary that matches your subtype.

The questions about preparation, documents and warning symptoms lower down do carry across.

NCI's clinical summary opens this section with a line most pages soften. No standard treatment regimen exists for refractory or recurrent acute myeloid leukemia.

That is not a gap in the writing. There is no single accepted best answer. It also explains why clinical trials sit high on the list here, not at the bottom.

Two words get mixed up and are worth splitting. Refractory means the leukemia never went into remission. Relapsed means it came back after one. That difference changes the odds.

Ask how long your first remission lasted, in months. That single fact shapes what salvage chemotherapy is likely to achieve, more than almost anything else on your chart. Our page on relapsed or refractory leukemia sets out the figures behind that.

It helps to know what counts as the leukemia getting worse, because the definition is numeric rather than impressionistic.

NCI's summary defines progressive disease by evidence of a rise in blasts. That means more than a 50% increase in marrow blasts, or more than a 50% increase in blasts in the blood without differentiation syndrome, or new disease outside the marrow.

So if the word progression is used, it is fair to ask which of those three applies.

NCI groups the options into three families: intensive salvage chemotherapy, reduced-intensity or targeted therapy, and a stem cell transplant using donor cells. Knowing which family is being proposed clarifies most of the conversation, so ask that first.

The regimens themselves, the response rates behind them, the FLT3 and CD19 and CD22 testing, and the questions to ask before a transplant are all set out on our page about relapsed or refractory leukemia. This page stays with the weeks around the news itself.

One thing to raise at this visit: ask whether the leukemia was tested again at relapse, not only at diagnosis. The genetic profile can change, and a targeted option can appear that was not there the first time. Liver blood tests are watched on some of those drugs, so ask what would pause treatment and who calls you.

APL is a separate subtype. NCI covers it in its own section. So a page about AML relapse can mislead here.

Recurrent APL is treated with arsenic trioxide, with or without chemotherapy. Stem cell transplant is also used. That is a different playbook from the salvage regimens above.

Newly diagnosed APL differs too. It uses all-trans retinoic acid and arsenic trioxide. Risk turns on the white blood cell count. Low to intermediate risk means a count of 10 x 10^9/L or less. NCI notes that lasting disease or relapse is rare in APL. Early deaths come from bleeding, differentiation syndrome, or infection, not resistant leukemia.

Three documents carry the weight. One is the original diagnostic report, with cytogenetics and molecular results. One is the record of first-line treatment and how long remission lasted. One is the current marrow report.

Ask for the proposed regimen by name. Then ask for its complete remission rate in the population closest to this one. No standard regimen exists here. That comparison is the most useful thing to carry out of the appointment. Our page on AML risk groups explains how the genetics were sorted at diagnosis.

• Call 911 or go to an emergency department if bleeding will not stop, or you cough up or vomit blood. Relapsed leukemia crowds out platelets, and APL in particular can cause severe bleeding and clots.
• Call 911 or go to an emergency department if you have a sudden severe headache, new confusion, weakness on one side, or trouble speaking. These can be signs of bleeding into the brain or of a clot.
• Call your leukemia team at once, day or night, if you have a temperature of 100.4°F (38°C) or higher, or chills. With white cells this low an infection can overwhelm the body in hours, so this is an emergency and needs antibiotics straight away. If you cannot get hold of the team quickly, go to an emergency department and tell them you have relapsed leukemia. The CDC treats fever during chemotherapy as a medical emergency.
• Call your care team the same day if you notice new bruises, nosebleeds, bleeding gums, blood in urine or stool, or a rash of tiny red or purple spots.
• Call your care team within a day or two if you are getting steadily more tired, breathless on light activity, or paler than usual. Those are the usual signs of falling red cells.

• National Cancer Institute, Acute Myeloid Leukemia Treatment (PDQ) - Health Professional Version, accessed August 6, 2026
• National Cancer Institute, Chronic Myelogenous Leukemia Treatment (PDQ) - Health Professional Version, accessed August 6, 2026
• National Cancer Institute, Acute Myeloid Leukemia Treatment (PDQ) - Patient Version, accessed August 11, 2026
• National Cancer Institute, Infection and Neutropenia During Cancer Treatment, accessed August 11, 2026